Mankind Pharma Q1 FY27 Revenue Grows 13% to ₹4,031 Crore; EBITDA Up 24.7%
Mankind Pharma reported Q1 FY27 revenue of ₹4,031 Crore, up 13% YoY. EBITDA increased by 24.7% to ₹1,060 Crore, and PAT rose 29.1% to ₹574 Crore. Domestic business grew 11.0%, exports 29%, and consumer healthcare 4%. EBITDA margins improved to 26.3%.
The announcement of quarterly financial results with significant growth and margin improvement is a material event for investors and directly impacts the company's valuation and stock performance.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with improvements in margins and key business segments, indicating a positive financial performance.
Mankind Pharma Limited announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27), reporting a revenue growth of approximately 13% year-on-year (YoY) to ₹4,031 Crore. The company's EBITDA saw a significant increase of 24.7% YoY, reaching ₹1,060 Crore. Profit After Tax (PAT) grew by 29.1% YoY to ₹574 Crore.
The domestic business, excluding Consumer Healthcare (CH), grew by 11.0% YoY, driven by double-digit growth in the Mankind domestic business, particularly in chronic segments like cardiac (19.4% growth) and anti-diabetes (12.7% growth). The Consumer Healthcare segment grew by approximately 4% YoY, while the international business expanded by 29% YoY.
The company highlighted improvements across key operating and financial metrics, attributing them to disciplined execution and strengthening business fundamentals. Gross Margins improved by 230 basis points to 72.8%, and EBITDA margins increased by 250 basis points to 26.3%. Adjusted EBITDA margins stood at 26.3%, and PAT margins were 14.2%.
Key financial metrics for Q1 FY27 include Revenue from Operations at ₹4,031 Crore, Gross Profit at ₹2,932 Crore, EBITDA at ₹1,060 Crore, and Profit After Tax at ₹574 Crore. Diluted EPS stood at ₹13.7, showing a 29.6% YoY increase.
The investor presentation also detailed segmental revenue breakup, showing Domestic Business at ₹3,426 Crore and Exports Business at ₹605 Crore. The company maintained its #1 rank in the domestic market for nine consecutive years with a prescription share of 15.2%. The presentation included a detailed breakdown of performance by therapy areas, brand performance, and consumer healthcare segment updates.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.